Enanta Pharmaceuticals (ENTA) Capital Expenditures Growth (5y) (2017 - 2025)
Enanta Pharmaceuticals (ENTA) Capital Expenditures Growth (5y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Enanta Pharmaceuticals | 369.97 Mn | 206.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -107.27% |
| Jun 30, 2025 | -3.99% |
| Mar 31, 2025 | 90.92% |
| Dec 31, 2024 | 37.83% |
| Sep 30, 2024 | 3.66% |
| Jun 30, 2024 | -19.37% |
| Mar 31, 2024 | 13.76% |
| Dec 31, 2023 | 4.52% |
| Sep 30, 2023 | -182.00% |
| Jun 30, 2023 | 48.07% |
| Mar 31, 2023 | 16.39% |
| Dec 31, 2022 | -60.25% |
| Sep 30, 2022 | 48.90% |
| Jun 30, 2022 | -20.32% |
| Mar 31, 2022 | -26.03% |
| Dec 31, 2021 | -45.46% |
| Jun 30, 2021 | -20.29% |
| Mar 31, 2021 | -38.79% |
| Dec 31, 2020 | -38.84% |
| Sep 30, 2020 | -18.85% |